Disease Detail

ID DOID:9256
Name colorectal cancer
Definition A large intestine cancer that is located_in the colon and/or located_in the rectum.
Source DiseaseOntology.org
Alt Ids
Path disease disease of cellular proliferation cancer organ system cancer gastrointestinal system cancer intestinal cancer large intestine cancer colorectal cancer

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
TP53 mutant PD0166285 colorectal cancer sensitive detail...
KRAS mutant Cetuximab colorectal cancer predicted - resistant detail...
Unknown unknown Panitumumab colorectal cancer not applicable detail...
Unknown unknown ABT-348 colorectal cancer not applicable detail...
TP53 loss Ad5CMV-p53 gene colorectal cancer predicted - sensitive detail...
Unknown unknown Danusertib colorectal cancer not applicable detail...
Unknown unknown PD-0325901 colorectal cancer not applicable detail...
Unknown unknown Fluorouracil + Leucovorin + Oxaliplatin + Ramucirumab colorectal cancer not applicable detail...
KRAS G13D Cetuximab colorectal cancer resistant detail...
KRAS wild-type Panitumumab colorectal cancer sensitive detail...
Unknown unknown GDC-0980 colorectal cancer not applicable detail...
KRAS mutant Bevacizumab colorectal cancer decreased response detail...
KRAS G12C Sunitinib colorectal cancer resistant detail...
KRAS G12D Sunitinib colorectal cancer resistant detail...
KRAS G13D Sunitinib colorectal cancer resistant detail...
KRAS G12S Sunitinib colorectal cancer resistant detail...
KRAS G12V Sunitinib colorectal cancer resistant detail...
TP53 mutant Bevacizumab colorectal cancer sensitive detail...
RET mutant Ponatinib colorectal cancer sensitive detail...
KRAS G12R Sunitinib colorectal cancer resistant detail...
Unknown unknown Adavosertib colorectal cancer not applicable detail...
BRAF mutant MLN2480 colorectal cancer sensitive detail...
Unknown unknown Cabozantinib colorectal cancer not applicable detail...
Unknown unknown MGCD516 colorectal cancer not applicable detail...
Unknown unknown Fluorouracil + Trametinib colorectal cancer not applicable detail...
NOTCH1 act mut PF-03084014 colorectal cancer sensitive detail...
Unknown unknown Vistusertib colorectal cancer not applicable detail...
KRAS wild-type Bevacizumab colorectal cancer sensitive detail...
BRAF V600E Regorafenib colorectal cancer sensitive detail...
Unknown unknown Afatinib colorectal cancer not applicable detail...
BRAF V600E Trametinib colorectal cancer sensitive detail...
BRAF V600E Sorafenib colorectal cancer sensitive detail...
BRAF V600E Dabrafenib colorectal cancer sensitive detail...
BRAF V600E Lapatinib + Panobinostat colorectal cancer sensitive detail...
BRAF V600E Gefitinib + Vemurafenib colorectal cancer sensitive detail...
BRAF V600E Erlotinib + Vemurafenib colorectal cancer sensitive detail...
BRAF V600E Cetuximab + Vemurafenib colorectal cancer sensitive detail...
Unknown unknown Capecitabine + Oxaliplatin + Vandetanib colorectal cancer not applicable detail...
BRAF V600E Encorafenib colorectal cancer sensitive detail...
KRAS G13D Cobimetinib colorectal cancer sensitive detail...
BRAF V600E Refametinib colorectal cancer sensitive detail...
BRAF V600E Dabrafenib + Panitumumab colorectal cancer sensitive detail...
Unknown unknown Fluorouracil + Quinacrine colorectal cancer not applicable detail...
Unknown unknown Fluorouracil + Quinacrine + Sorafenib colorectal cancer not applicable detail...
KRAS mutant Trametinib colorectal cancer sensitive detail...
KRAS G13D Oxaliplatin colorectal cancer sensitive detail...
KRAS G12V Oxaliplatin colorectal cancer sensitive detail...
KRAS G13X Oxaliplatin colorectal cancer sensitive detail...
KRAS wild-type Panitumumab + Rilotumumab colorectal cancer sensitive detail...
KRAS G12X Panitumumab colorectal cancer resistant detail...
KRAS G13X Panitumumab colorectal cancer resistant detail...
KRAS A146T PD-0325901 colorectal cancer sensitive detail...
KRAS A146T Cetuximab colorectal cancer resistant detail...
APC inact mut Celecoxib + Erlotinib colorectal cancer sensitive detail...
APC inact mut Celecoxib colorectal cancer sensitive detail...
APC inact mut Sulindac colorectal cancer sensitive detail...
APC inact mut Erlotinib + Ibuprofen colorectal cancer sensitive detail...
APC inact mut Dasatinib colorectal cancer sensitive detail...
Unknown unknown Rucaparib + Temozolomide colorectal cancer not applicable detail...
RET M918T Sorafenib colorectal cancer sensitive detail...
Unknown unknown Nintedanib colorectal cancer not applicable detail...
BRAF V600E Panitumumab + Vemurafenib colorectal cancer sensitive detail...
Unknown unknown Regorafenib colorectal cancer not applicable detail...
Unknown unknown Bevacizumab + Fluorouracil + Irinotecan + Leucovorin colorectal cancer not applicable detail...
Unknown unknown Aflibercept colorectal cancer not applicable detail...
Unknown unknown Fluorouracil + Irinotecan + Leucovorin + Ramucirumab colorectal cancer not applicable detail...
KRAS exon 2 Irinotecan + Selumetinib colorectal cancer predicted - sensitive detail...
KRAS mutant Fluorouracil + Irinotecan + Leucovorin + Ramucirumab colorectal cancer sensitive detail...
BRAF V600X Dabrafenib + Trametinib colorectal cancer sensitive detail...
Unknown unknown INCB054329 colorectal cancer not applicable detail...
Unknown unknown Merestinib colorectal cancer not applicable detail...
BRAF V600E Selumetinib colorectal cancer sensitive detail...
KRAS mutant BEZ235 colorectal cancer sensitive detail...
KRAS mutant CI-1040 colorectal cancer sensitive detail...
KRAS mutant RO4987655 colorectal cancer no benefit detail...
KRAS mutant Pimasertib + SAR245409 colorectal cancer sensitive detail...
Unknown unknown WAY-600 colorectal cancer not applicable detail...
Unknown unknown WYE-354 colorectal cancer not applicable detail...
Unknown unknown WYE-687 colorectal cancer not applicable detail...
APC inact mut XAV939 colorectal cancer sensitive detail...
APC inact mut PKF118-310 colorectal cancer sensitive detail...
APC inact mut CCT036477 colorectal cancer sensitive detail...
APC inact mut CCT070535 colorectal cancer sensitive detail...
APC inact mut CCT031374 colorectal cancer sensitive detail...
APC inact mut NC043 colorectal cancer sensitive detail...
CTNNB1 mutant BC21 colorectal cancer sensitive detail...
APC inact mut Pyrvinium colorectal cancer sensitive detail...
APC inact mut Niclosamide colorectal cancer sensitive detail...
ERBB2 amp Trastuzumab colorectal cancer resistant detail...
ERBB2 amp Lapatinib colorectal cancer decreased response detail...
ERBB2 amp Lapatinib + Trastuzumab colorectal cancer sensitive detail...
ERBB2 amp Cetuximab colorectal cancer resistant detail...
KRAS wild-type Fluorouracil + Irinotecan + Oxaliplatin + Panitumumab colorectal cancer sensitive detail...
KRAS G12X Fluorouracil + Irinotecan + Oxaliplatin + Panitumumab colorectal cancer no benefit detail...
KRAS G13X Fluorouracil + Irinotecan + Oxaliplatin + Panitumumab colorectal cancer no benefit detail...
KRAS mutant Fluorouracil + Irinotecan + Oxaliplatin + Panitumumab colorectal cancer no benefit detail...
NRAS wild-type Panitumumab colorectal cancer predicted - sensitive detail...
APC Q1338* JW67 colorectal cancer sensitive detail...
APC Q1338* JW74 colorectal cancer sensitive detail...
APC mutant JW74 colorectal cancer sensitive detail...
BRAF V600X Vemurafenib colorectal cancer no benefit detail...
BRAF V600X Cetuximab + Vemurafenib colorectal cancer sensitive detail...
BRAF V600E CCT196969 colorectal cancer sensitive detail...
BRAF V600E CCT241161 colorectal cancer sensitive detail...
Unknown unknown Tanibirumab colorectal cancer not applicable detail...
Unknown unknown Fluorouracil + Tanibirumab colorectal cancer not applicable detail...
KRAS mutant Cetuximab + Fluorouracil + Irinotecan + Leucovorin colorectal cancer no benefit detail...
NRAS mutant Cetuximab + Fluorouracil + Irinotecan + Leucovorin colorectal cancer no benefit detail...
KRAS wild-type Cetuximab + Fluorouracil + Irinotecan + Leucovorin colorectal cancer predicted - sensitive detail...
NRAS wild-type Cetuximab + Fluorouracil + Irinotecan + Leucovorin colorectal cancer predicted - sensitive detail...
TP53 mutant Pazopanib + Vorinostat colorectal cancer sensitive detail...
AKT1 E17K KRAS wild-type BRAF wild-type Cetuximab + Irinotecan colorectal cancer predicted - resistant detail...
SMAD4 dec exp N/A colorectal cancer not applicable detail...
Unknown unknown Conatumumab + Ganitumab colorectal cancer not applicable detail...
ALK fusion Entrectinib colorectal cancer sensitive detail...
FGFR2 amp Debio 1347 colorectal cancer sensitive detail...
ARID1A Q456* Olaparib colorectal cancer sensitive detail...
APC mutant G-631 colorectal cancer no benefit detail...
ARID1A Q456* Talazoparib colorectal cancer sensitive detail...
KRAS wild-type Fluorouracil + Leucovorin + Necitumumab + Oxaliplatin colorectal cancer predicted - sensitive detail...
KRAS mutant Fluorouracil + Leucovorin + Necitumumab + Oxaliplatin colorectal cancer predicted - sensitive detail...
MAP2K1 K57T Cetuximab colorectal cancer predicted - resistant detail...
MAP2K1 K57T Panitumumab colorectal cancer resistant detail...
MAP2K1 K57N Cetuximab colorectal cancer resistant detail...
MAP2K1 K57N Panitumumab colorectal cancer resistant detail...
MAP2K1 K57T Cetuximab + Trametinib colorectal cancer sensitive detail...
MAP2K1 K57N Cetuximab + Trametinib colorectal cancer sensitive detail...
MAP2K1 K57N Panitumumab + Trametinib colorectal cancer sensitive detail...
MAP2K1 K57T Panitumumab + Trametinib colorectal cancer sensitive detail...
ARID1A Q456* Rucaparib colorectal cancer sensitive detail...
Unknown unknown SKF-96365 colorectal cancer not applicable detail...
Unknown unknown Enadenotucirev colorectal cancer not applicable detail...
KRAS G12A Cetuximab colorectal cancer sensitive detail...
KRAS G12V Cetuximab colorectal cancer resistant detail...
KRAS G13D Regorafenib colorectal cancer resistant detail...
KRAS G12V Regorafenib colorectal cancer resistant detail...
KRAS G12A Regorafenib colorectal cancer resistant detail...
KRAS G12V Cetuximab + Regorafenib colorectal cancer sensitive detail...
KRAS G13D Cetuximab + Regorafenib colorectal cancer sensitive detail...
BRAF V600E BI 882370 + Cetuximab colorectal cancer sensitive detail...
BRAF V600E Afatinib + BI 882370 colorectal cancer sensitive detail...
BRAF V600E BI 882370 + Trametinib colorectal cancer sensitive detail...
IDH1 R132H Metformin colorectal cancer sensitive detail...
Unknown unknown TAK-960 colorectal cancer not applicable detail...
IDH1 R132H AGI-5198 + Metformin colorectal cancer resistant detail...
KRAS wild-type Napabucasin + Panitumumab colorectal cancer predicted - sensitive detail...
BRCA2 loss YU238259 colorectal cancer sensitive detail...
BRCA2 loss Etoposide + YU238259 colorectal cancer sensitive detail...
BRCA2 loss Radiotherapy + YU238259 colorectal cancer sensitive detail...
BRCA2 loss Olaparib + YU238259 colorectal cancer sensitive detail...
IDH1 R132H AGI-5198 + Radiotherapy colorectal cancer resistant detail...
APC mutant KRAS mutant KDR R961W Regorafenib colorectal cancer predicted - sensitive detail...
Unknown unknown Cetuximab + Fluorouracil + Leucovorin + Oxaliplatin colorectal cancer not applicable detail...
KRAS G13D Palbociclib + Trametinib colorectal cancer sensitive detail...
KRAS mutant Palbociclib + Trametinib colorectal cancer sensitive detail...
BRAF V600E KRAS wild-type Palbociclib + Trametinib colorectal cancer no benefit detail...
TP53 wild-type Prodigiosin colorectal cancer sensitive detail...
TP53 mutant Prodigiosin colorectal cancer sensitive detail...
TP53 loss Prodigiosin colorectal cancer sensitive detail...
BRAF V600E PD-0325901 colorectal cancer sensitive detail...
BRAF V600E SCH772984 colorectal cancer sensitive detail...
KRAS mutant DEL-22379 colorectal cancer sensitive detail...
MLH1 inact mut N/A colorectal cancer not applicable detail...
BRAF V600E KRAS mutant PD-0325901 colorectal cancer resistant detail...
BRAF V600E KRAS mutant DEL-22379 colorectal cancer sensitive detail...
Unknown unknown ST7612AA1 colorectal cancer not applicable detail...
KRAS mutant Regorafenib colorectal cancer no benefit detail...
Unknown unknown YW3-56 colorectal cancer not applicable detail...
FLT3 amp Sorafenib colorectal cancer predicted - sensitive detail...
MSH6 mutant N/A colorectal cancer not applicable detail...
Unknown unknown Dbait + Fluorouracil + Oxaliplatin colorectal cancer not applicable detail...
BRAF V600E DT01 + Fluorouracil + Oxaliplatin colorectal cancer sensitive detail...
STAG2 dec exp Olaparib colorectal cancer sensitive detail...
Unknown unknown AB61 colorectal cancer not applicable detail...
Unknown unknown Refametinib + Sorafenib colorectal cancer not applicable detail...
MAP2K1 F53L Trametinib colorectal cancer sensitive detail...
ERBB2 positive KRAS wild-type Lapatinib + Trastuzumab colorectal cancer sensitive detail...
Unknown unknown ABT-751 + Bevacizumab + Capecitabine + Irinotecan colorectal cancer no benefit detail...
KRAS G13D LY3009120 colorectal cancer sensitive detail...
ATM loss VX-970 colorectal cancer sensitive detail...
Unknown unknown MM-151 colorectal cancer not applicable detail...
BRAF mutant Trametinib colorectal cancer resistant detail...
Unknown unknown trifluridine/tipiracil hydrochloride colorectal cancer not applicable detail...
KRAS wild-type Bevacizumab + Capecitabine colorectal cancer predicted - sensitive detail...
BRAF mutant Alpelisib + Cetuximab + Encorafenib colorectal cancer sensitive detail...
KRAS wild-type Cabozantinib + Panitumumab colorectal cancer sensitive detail...
Unknown unknown Binimetinib + Fluorouracil + Leucovorin + Oxaliplatin colorectal cancer not applicable detail...
ERBB2 V842I Cetuximab colorectal cancer resistant detail...
ERBB2 V842I Panitumumab colorectal cancer resistant detail...
ERBB2 L755S Cetuximab colorectal cancer resistant detail...
ERBB2 L755S Panitumumab colorectal cancer resistant detail...
ERBB2 V777L Cetuximab colorectal cancer resistant detail...
ERBB2 V777L Panitumumab colorectal cancer resistant detail...
ERBB2 L866M Cetuximab colorectal cancer resistant detail...
ERBB2 L866M Panitumumab colorectal cancer resistant detail...
ERBB2 S310F Cetuximab colorectal cancer resistant detail...
ERBB2 S310F Panitumumab colorectal cancer resistant detail...
ERBB2 L755S Neratinib colorectal cancer sensitive detail...
ERBB2 V777L Neratinib colorectal cancer conflicting detail...
ERBB2 L866M Neratinib colorectal cancer sensitive detail...
ERBB2 S310F Neratinib colorectal cancer conflicting detail...
ERBB2 V842I Neratinib colorectal cancer conflicting detail...
ERBB2 L755S Afatinib colorectal cancer sensitive detail...
ERBB2 V777L Afatinib colorectal cancer sensitive detail...
ERBB2 L866M Afatinib colorectal cancer sensitive detail...
ERBB2 S310F Afatinib colorectal cancer sensitive detail...
ERBB2 V842I Afatinib colorectal cancer sensitive detail...
ERBB2 V777L Neratinib + Trastuzumab colorectal cancer sensitive detail...
KRAS G12V Neratinib colorectal cancer decreased response detail...
KRAS G13D Neratinib colorectal cancer decreased response detail...
ERBB2 S310Y Cetuximab colorectal cancer resistant detail...
ERBB2 amp ERBB2 L866M Cetuximab colorectal cancer resistant detail...
ERBB2 S310Y Trastuzumab colorectal cancer sensitive detail...
ERBB2 S310Y Neratinib colorectal cancer sensitive detail...
ERBB2 S310Y Lapatinib colorectal cancer sensitive detail...
ERBB2 S310Y Neratinib + Trastuzumab colorectal cancer sensitive detail...
ERBB2 S310Y Lapatinib + Trastuzumab colorectal cancer sensitive detail...
ERBB2 amp ERBB2 L866M Trastuzumab colorectal cancer resistant detail...
ERBB2 amp ERBB2 L866M Neratinib colorectal cancer sensitive detail...
ERBB2 amp ERBB2 L866M Neratinib + Trastuzumab colorectal cancer sensitive detail...
KRAS G12D Neratinib colorectal cancer resistant detail...
KRAS G12D Neratinib + Trastuzumab colorectal cancer resistant detail...
KRAS mutant Atezolizumab + Cobimetinib colorectal cancer predicted - sensitive detail...
APC mutant K-756 colorectal cancer predicted - sensitive detail...
FGFR1 dec exp KRAS mut Trametinib colorectal cancer no benefit detail...
Unknown unknown Abemaciclib colorectal cancer not applicable detail...
KRAS mutant TP53 mutant Abemaciclib colorectal cancer sensitive detail...
Unknown unknown Olaparib colorectal cancer no benefit detail...
KRAS mutant SHP099 colorectal cancer predicted - resistant detail...
BRAF V600E SHP099 colorectal cancer resistant detail...
KRAS mutant Ixabepilone + Sunitinib colorectal cancer predicted - sensitive detail...
Unknown unknown IMC-3C5 colorectal cancer not applicable detail...
BRAF V600E Vemurafenib colorectal cancer no benefit detail...
BRAF V600E Cetuximab + Selumetinib colorectal cancer sensitive detail...
BRAF V600E MAP2K1 L115P Dabrafenib + Trametinib colorectal cancer resistant detail...
BRAF V600E KRAS G13D Cetuximab + Encorafenib colorectal cancer resistant detail...
BRAF V600E KRAS A146T Cetuximab + Encorafenib colorectal cancer resistant detail...
BRAF V600E KRAS A146T Cetuximab + Dabrafenib colorectal cancer resistant detail...
BRAF V600E KRAS amp Cetuximab + Dabrafenib colorectal cancer resistant detail...
BRAF V600E KRAS G12D Cetuximab + Vemurafenib colorectal cancer resistant detail...
BRAF V600E KRAS A146T KRAS A146V Alpelisib + Cetuximab + Encorafenib colorectal cancer resistant detail...
BRAF V600E MAP2K1 V211D Cetuximab + Selumetinib colorectal cancer resistant detail...
BRAF amp BRAF V600E Cetuximab + Selumetinib colorectal cancer resistant detail...
BRAF V600E Cetuximab + Encorafenib colorectal cancer sensitive detail...
BRAF V600E Cetuximab + Dabrafenib colorectal cancer sensitive detail...
BRAF V600E Alpelisib + Cetuximab + Encorafenib colorectal cancer sensitive detail...
BRAF V600E Dabrafenib + Trametinib colorectal cancer sensitive detail...
BRAF V600E Cetuximab + Dabrafenib + Trametinib colorectal cancer sensitive detail...
BRAF V600E Cetuximab + SCH772984 colorectal cancer sensitive detail...
BRAF V600E Dabrafenib + SCH772984 colorectal cancer sensitive detail...
BRAF V600E Cetuximab + Dabrafenib + SCH772984 colorectal cancer sensitive detail...
BRAF V600E MAP2K1 L115P Cetuximab + Encorafenib colorectal cancer sensitive detail...
BRAF V600E MAP2K1 L115P Cetuximab + Dabrafenib colorectal cancer sensitive detail...
BRAF V600E MAP2K1 L115P Cetuximab + Vemurafenib colorectal cancer sensitive detail...
BRAF V600E MAP2K1 L115P Alpelisib + Cetuximab + Encorafenib colorectal cancer sensitive detail...
BRAF V600E MAP2K1 L115P Cetuximab + Dabrafenib + Trametinib colorectal cancer sensitive detail...
BRAF V600E MAP2K1 L115P SCH772984 colorectal cancer sensitive detail...
BRAF V600E MAP2K1 L115P Cetuximab + SCH772984 colorectal cancer sensitive detail...
BRAF V600E MAP2K1 L115P Dabrafenib + SCH772984 colorectal cancer sensitive detail...
BRAF V600E MAP2K1 L115P Cetuximab + Dabrafenib + SCH772984 colorectal cancer sensitive detail...
BRAF V600E KRAS G13D Cetuximab + Dabrafenib colorectal cancer resistant detail...
Unknown unknown CBP501 + Cisplatin colorectal cancer not applicable detail...
Unknown unknown Bleomycin + CBP501 colorectal cancer not applicable detail...
BRAF V600E KRAS G13D Cetuximab + Vemurafenib colorectal cancer resistant detail...
BRAF V600E KRAS G13D Alpelisib + Cetuximab + Encorafenib colorectal cancer resistant detail...
BRAF V600E KRAS G13D Cetuximab + Selumetinib colorectal cancer resistant detail...
BRAF V600E KRAS G13D Dabrafenib + Trametinib colorectal cancer resistant detail...
BRAF V600E KRAS G13D Cetuximab + Dabrafenib + Trametinib colorectal cancer resistant detail...
BRAF V600E KRAS G13D SCH772984 colorectal cancer resistant detail...
BRAF V600E KRAS G13D Cetuximab + SCH772984 colorectal cancer resistant detail...
BRAF V600E KRAS A146T Cetuximab + Vemurafenib colorectal cancer resistant detail...
BRAF V600E KRAS A146T Cetuximab + Dabrafenib + Trametinib colorectal cancer sensitive detail...
BRAF V600E KRAS amp Cetuximab + Encorafenib colorectal cancer resistant detail...
BRAF V600E KRAS amp Cetuximab + Vemurafenib colorectal cancer resistant detail...
BRAF V600E KRAS amp SCH772984 colorectal cancer resistant detail...
BRAF V600E KRAS amp Dabrafenib + SCH772984 colorectal cancer resistant detail...
BRAF V600E KRAS A146T Alpelisib + Cetuximab + Encorafenib colorectal cancer resistant detail...
BRAF V600E KRAS G12D Alpelisib + Cetuximab + Encorafenib colorectal cancer resistant detail...
BRAF V600E KRAS G12D Cetuximab + Dabrafenib + Trametinib colorectal cancer sensitive detail...
BRAF V600E KRAS G12D Cetuximab + SCH772984 colorectal cancer sensitive detail...
BRAF V600E KRAS A146T KRAS A146V Cetuximab + Encorafenib colorectal cancer resistant detail...
BRAF V600E KRAS A146T KRAS A146V Cetuximab + Dabrafenib colorectal cancer resistant detail...
BRAF V600E KRAS A146T KRAS A146V Cetuximab + Vemurafenib colorectal cancer resistant detail...
BRAF V600E KRAS A146T KRAS A146V Cetuximab + Selumetinib colorectal cancer resistant detail...
BRAF V600E MAP2K1 V211D Cetuximab + Encorafenib colorectal cancer resistant detail...
BRAF V600E MAP2K1 V211D Dabrafenib + Trametinib colorectal cancer resistant detail...
BRAF V600E MAP2K1 V211D Cetuximab + Dabrafenib + Trametinib colorectal cancer resistant detail...
BRAF V600E MAP2K1 V211D SCH772984 colorectal cancer resistant detail...
BRAF amp BRAF V600E Cetuximab + Vemurafenib colorectal cancer resistant detail...
BRAF amp BRAF V600E SCH772984 colorectal cancer resistant detail...
MAP2K1 F129L RO4927350 colorectal cancer sensitive detail...
BRAF V600E PLX7904 colorectal cancer sensitive detail...
BRAF V600E TAK-632 colorectal cancer sensitive detail...
BRAF V600E PLX4720 + TAK-632 colorectal cancer sensitive detail...
ARID1A Q456* Dasatinib colorectal cancer sensitive detail...
BRAF V600E BGB-283 colorectal cancer sensitive detail...
BRAF V600E BGB-283 + Cetuximab colorectal cancer sensitive detail...
KRAS mut + TP53 wild-type AMG 232 colorectal cancer sensitive detail...
KRAS mut + TP53 wild-type AMG 232 + Irinotecan colorectal cancer sensitive detail...
KRAS wild-type Cetuximab + Lenalidomide colorectal cancer predicted - sensitive detail...
BRAF V600E Pimasertib colorectal cancer sensitive detail...
KRAS G13D Pimasertib colorectal cancer decreased response detail...
BRAF V600E Everolimus + Pimasertib colorectal cancer sensitive detail...
KRAS G13D Everolimus + Pimasertib colorectal cancer sensitive detail...
BRAF V600E Pimasertib + Sorafenib colorectal cancer sensitive detail...
KRAS G13D Pimasertib + Sorafenib colorectal cancer sensitive detail...
BRAF V600E Pimasertib + Regorafenib colorectal cancer sensitive detail...
KRAS G13D Pimasertib + Regorafenib colorectal cancer sensitive detail...
TP53 mutant NSC59984 colorectal cancer predicted - sensitive detail...
TP53 R175L NSC59984 colorectal cancer sensitive detail...
TP53 R175H NSC59984 colorectal cancer sensitive detail...
TP53 R273H TP53 P309S NSC59984 colorectal cancer sensitive detail...
TP53 R273H TP53 P309S Cisplatin + NSC59984 colorectal cancer sensitive detail...
Unknown unknown Demcizumab colorectal cancer not applicable detail...
Unknown unknown Napabucasin colorectal cancer not applicable detail...
Unknown unknown Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin colorectal cancer not applicable detail...
KRAS G13D Rigosertib colorectal cancer sensitive detail...
BRAF V600E PTEN loss TP53 wild-type PD-0325901 + Sapanisertib colorectal cancer sensitive detail...
TP53 wild-type PD-0325901 + Sapanisertib colorectal cancer predicted - sensitive detail...
KRAS G12D PTEN loss TP53 V216M PD-0325901 + Sapanisertib colorectal cancer no benefit detail...
KRAS G12D PTEN dec exp TP53 R306* PD-0325901 + Sapanisertib colorectal cancer no benefit detail...
BRAF mutant PLX4720 colorectal cancer decreased response detail...
BRAF mut PTPN11 dec exp PLX4720 colorectal cancer sensitive detail...
BRAF mutant AZ628 + Selumetinib colorectal cancer sensitive detail...
KRAS act mut AZ628 + Selumetinib colorectal cancer sensitive detail...
Unknown unknown OSI-027 colorectal cancer not applicable detail...
Unknown unknown Fluorouracil + Leucovorin + Oxaliplatin + Tivozanib colorectal cancer no benefit detail...
Unknown unknown Olaparib + Temozolomide colorectal cancer not applicable detail...
Unknown unknown AZD2461 + Temozolomide colorectal cancer not applicable detail...
APC wild-type TASIN-1 colorectal cancer resistant detail...
APC inact mut TASIN-1 colorectal cancer sensitive detail...
APC E1309* TASIN-1 colorectal cancer sensitive detail...
APC E853* APC K1555* TASIN-1 colorectal cancer sensitive detail...
APC Q1131* APC Q1303* TASIN-1 colorectal cancer sensitive detail...
APC Q1338* TASIN-1 colorectal cancer sensitive detail...
APC L1488* TASIN-1 colorectal cancer sensitive detail...
APC G1416* TASIN-1 colorectal cancer sensitive detail...
FGFR2 over exp BAY1187982 colorectal cancer sensitive detail...
APC inact mut PTEN inact mut BEZ235 colorectal cancer sensitive detail...
APC inact mut KRAS G12D BEZ235 colorectal cancer sensitive detail...
APC inact mut KRAS G12D PTEN inact mut BEZ235 colorectal cancer sensitive detail...
APC inact mut PTEN inact mut Binimetinib colorectal cancer no benefit detail...
APC inact mut KRAS G12D Binimetinib colorectal cancer sensitive detail...
APC inact mut KRAS G12D PTEN inact mut Binimetinib colorectal cancer no benefit detail...
APC inact mut PTEN inact mut BEZ235 + Binimetinib colorectal cancer no benefit detail...
APC inact mut KRAS G12D BEZ235 + Binimetinib colorectal cancer sensitive detail...
APC inact mut KRAS G12D PTEN inact mut BEZ235 + Binimetinib colorectal cancer sensitive detail...
KRAS G12D KRAS mutant-specific TIL colorectal cancer predicted - sensitive detail...
BRAF V600X Cetuximab + Irinotecan + Vemurafenib colorectal cancer sensitive detail...
Unknown unknown Bevacizumab + Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin colorectal cancer not applicable detail...
KRAS mutant TP53 mutant Alpelisib + Erlotinib + Navitoclax + Trametinib colorectal cancer sensitive detail...
BRAF mut + TP53 wild-type CGM097 + Dabrafenib + Navitoclax + PF-04217903 colorectal cancer sensitive detail...
BRAF mut TP53 mut Alpelisib + Dabrafenib + Erlotinib + Navitoclax colorectal cancer sensitive detail...
KRAS mut + TP53 wild-type Alpelisib + CGM097 + Navitoclax + Trametinib colorectal cancer sensitive detail...
Unknown unknown Balsalazide + Parthenolide colorectal cancer not applicable detail...
TP53 loss AZD6738 + Radiotherapy colorectal cancer sensitive detail...
KRAS act mut VX-11e + WEHI-539 colorectal cancer predicted - sensitive detail...
BRAF act mut VX-11e + WEHI-539 colorectal cancer predicted - sensitive detail...
KRAS act mut Venetoclax + VX-11e colorectal cancer no benefit detail...
BRAF act mut Venetoclax + VX-11e colorectal cancer no benefit detail...
MAP2K1 F53L Cetuximab colorectal cancer resistant detail...
MAP2K1 C121S Cetuximab colorectal cancer resistant detail...
MAP2K1 F53L Cetuximab + Trametinib colorectal cancer sensitive detail...
MAP2K1 C121S Cetuximab + Trametinib colorectal cancer sensitive detail...
KRAS G12C Cetuximab + Trametinib colorectal cancer sensitive detail...
NRAS G12V Cetuximab + Trametinib colorectal cancer sensitive detail...
NRAS G12V Cetuximab colorectal cancer resistant detail...
Unknown unknown CCT137690 + Radiotherapy colorectal cancer not applicable detail...
TP53 loss PHA-680632 + Radiotherapy colorectal cancer sensitive detail...
KRAS mutant Binimetinib colorectal cancer predicted - sensitive detail...
BRAF mutant Binimetinib colorectal cancer predicted - sensitive detail...
KRAS exon 2 Cetuximab + Selumetinib colorectal cancer no benefit detail...
APC S811* G007-LK colorectal cancer sensitive detail...
APC S1197* APC S1278* G007-LK colorectal cancer sensitive detail...
APC L665* APC R1450* G007-LK colorectal cancer resistant detail...
APC E853* APC T1556fs G007-LK colorectal cancer resistant detail...
APC N1819fs APC wild-type G007-LK colorectal cancer resistant detail...
APC S811* IWR-1 colorectal cancer sensitive detail...
APC S1197* APC S1278* IWR-1 colorectal cancer sensitive detail...
APC E853* APC T1556fs IWR-1 colorectal cancer resistant detail...
APC L665* APC R1450* IWR-1 colorectal cancer sensitive detail...
APC N1819fs IWR-1 colorectal cancer resistant detail...
APC S811* XAV939 colorectal cancer sensitive detail...
APC S1197* APC S1278* XAV939 colorectal cancer sensitive detail...
APC N1819fs APC wild-type XAV939 colorectal cancer resistant detail...
APC L665* APC R1450* XAV939 colorectal cancer sensitive detail...
APC E853* APC T1556fs XAV939 colorectal cancer resistant detail...
APC R216* G007-LK colorectal cancer sensitive detail...
APC R216* IWR-1 colorectal cancer sensitive detail...
APC I1164fs G007-LK colorectal cancer sensitive detail...
APC I1164fs IWR-1 colorectal cancer sensitive detail...
APC W553* IWR-1 colorectal cancer sensitive detail...
APC W553* G007-LK colorectal cancer sensitive detail...
TP53 wild-type MK-8745 colorectal cancer predicted - sensitive detail...
TP53 del TC-A2317 colorectal cancer predicted - sensitive detail...
IDH2 R172K Enasidenib colorectal cancer predicted - sensitive detail...
KRAS G12V 3144 colorectal cancer sensitive detail...
KRAS mutant Reolysin colorectal cancer sensitive detail...
KRAS mutant Irinotecan + Reolysin colorectal cancer sensitive detail...
TP53 del Doxorubicin + Seliciclib colorectal cancer predicted - sensitive detail...
Unknown unknown MCLA-128 colorectal cancer not applicable detail...
Unknown unknown Pegilodecakin colorectal cancer not applicable detail...
Unknown unknown V158411 colorectal cancer not applicable detail...
Unknown unknown CVX-060 colorectal cancer not applicable detail...
TP53 wild-type ALRN-6924 colorectal cancer sensitive detail...
PTEN loss AZD8186 + Vistusertib colorectal cancer sensitive detail...
Unknown unknown UD-017 colorectal cancer not applicable detail...
FGFR2 amp Erdafitinib colorectal cancer sensitive detail...
Unknown unknown Resminostat colorectal cancer not applicable detail...
Unknown unknown Oxaliplatin + Resminostat colorectal cancer not applicable detail...
BRAF mutant Cetuximab + Encorafenib colorectal cancer sensitive detail...
KRAS wild-type Cetuximab colorectal cancer predicted - sensitive detail...
KRAS G12V AZD4785 colorectal cancer sensitive detail...
KRAS wild-type AZD4785 colorectal cancer decreased response detail...
MET amp Cetuximab colorectal cancer resistant detail...
MET amp JNJ 38877605 colorectal cancer sensitive detail...
MET over exp Cetuximab colorectal cancer resistant detail...
MET over exp Panitumumab colorectal cancer resistant detail...
MET over exp Cetuximab + JNJ 38877605 colorectal cancer sensitive detail...
MET over exp JNJ 38877605 + Panitumumab colorectal cancer sensitive detail...
ERBB2 over exp Cetuximab colorectal cancer resistant detail...
Unknown unknown Navitoclax + TAK-901 colorectal cancer not applicable detail...
ERBB2 amp Cetuximab + Lapatinib colorectal cancer sensitive detail...
ERBB2 amp Lapatinib + Pertuzumab colorectal cancer sensitive detail...
ERBB2 amp Pertuzumab colorectal cancer no benefit detail...
Unknown unknown Bevacizumab + Fluorouracil + Irinotecan + Oxaliplatin colorectal cancer not applicable detail...
Unknown unknown Nivolumab colorectal cancer not applicable detail...
BRAF G596R Trametinib colorectal cancer sensitive detail...
BRAF G466V Cetuximab colorectal cancer sensitive detail...
BRAF G466V Trametinib colorectal cancer sensitive detail...
BRAF G466V Vemurafenib colorectal cancer no benefit detail...
BRAF G466V Irinotecan + Panitumumab colorectal cancer predicted - sensitive detail...
BRAF G596R Vemurafenib colorectal cancer resistant detail...
Unknown unknown Barasertib + Navitoclax colorectal cancer not applicable detail...
BRAF mutant KO-947 colorectal cancer predicted - sensitive detail...
NRAS mutant KO-947 colorectal cancer predicted - sensitive detail...
BRAF G596R Dabrafenib + Trametinib colorectal cancer sensitive detail...
Unknown unknown ETBX-011 colorectal cancer not applicable detail...
ARID1A Q456* VE-821 colorectal cancer sensitive detail...
ARID1A Q456* VX-970 colorectal cancer sensitive detail...
BRAF V600E Cetuximab + PLX4720 colorectal cancer sensitive detail...
BRAF mutant Dabrafenib + Panitumumab + Trametinib colorectal cancer predicted - sensitive detail...
Unknown unknown Ibrutinib + unspecified CTLA4 antibody colorectal cancer not applicable detail...
BRAF V600E Cobimetinib + Vemurafenib colorectal cancer sensitive detail...
FBXW7 R505C Regorafenib colorectal cancer resistant detail...
KRAS mutant KO-947 colorectal cancer predicted - sensitive detail...
ERBB2 positive DS-8201a colorectal cancer predicted - sensitive detail...
KRAS G12V Alpelisib colorectal cancer sensitive detail...
ERBB2 positive ZW25 colorectal cancer no benefit detail...
BRAF V600E INU-152 colorectal cancer sensitive detail...
Unknown unknown Bevacizumab + Capecitabine colorectal cancer not applicable detail...
BRAF wild-type KRAS wild-type LSN3074753 colorectal cancer decreased response detail...
KRAS mutant LSN3074753 colorectal cancer predicted - sensitive detail...
BRAF mutant LSN3074753 colorectal cancer predicted - sensitive detail...
BRAF V600E LSN3074753 colorectal cancer predicted - sensitive detail...
KRAS G12D LSN3074753 colorectal cancer predicted - sensitive detail...
BRAF mutant Cetuximab + LSN3074753 colorectal cancer sensitive detail...
KRAS mutant Cetuximab + LSN3074753 colorectal cancer sensitive detail...
KRAS G12D Cetuximab + LSN3074753 colorectal cancer sensitive detail...
BRAF G596V NRAS G13R Cetuximab + LSN3074753 colorectal cancer sensitive detail...
BRAF V600E EBI-907 colorectal cancer sensitive detail...
KRAS G12D ST-162 colorectal cancer sensitive detail...
KRAS G12D PD-0325901 + ZSTK474 colorectal cancer sensitive detail...
Unknown unknown ST-162 + unspecified PD-1 antibody colorectal cancer predicted - sensitive detail...
MET wild-type Glesatinib colorectal cancer decreased response detail...
Unknown unknown Gedatolisib + Irinotecan colorectal cancer not applicable detail...
Unknown unknown CCT241533 + Rucaparib colorectal cancer not applicable detail...
ERBB2 mutant Neratinib colorectal cancer no benefit detail...
ERBB2 D769H Neratinib colorectal cancer predicted - resistant detail...
ERBB2 G778A Neratinib colorectal cancer predicted - resistant detail...
ERBB2 K831N Neratinib colorectal cancer predicted - resistant detail...
ERBB2 L841V Neratinib colorectal cancer predicted - resistant detail...
ERBB2 R678Q Neratinib colorectal cancer predicted - resistant detail...
ERBB2 V777L ERBB2 V842I Neratinib colorectal cancer predicted - resistant detail...
BRAF wild-type KRAS wild-type NRAS wild-type Cetuximab + Fluorouracil + Irinotecan + Leucovorin colorectal cancer predicted - sensitive detail...
BRAF wild-type KRAS wild-type NRAS wild-type Bevacizumab + Cetuximab + Fluorouracil + Irinotecan + Leucovorin colorectal cancer predicted - sensitive detail...
Unknown unknown ICEC0942 colorectal cancer sensitive detail...
KRAS mutant Fluorouracil + Irinotecan + Leucovorin + Simtuzumab colorectal cancer no benefit detail...
BRAF V600E Dabrafenib + Panitumumab + Trametinib colorectal cancer predicted - sensitive detail...
BRAF V600E Panitumumab + Trametinib colorectal cancer no benefit detail...
Unknown unknown Utomilumab colorectal cancer no benefit detail...
Unknown unknown Atezolizumab + Cobimetinib colorectal cancer no benefit detail...
KRAS wild-type SYM004 colorectal cancer no benefit detail...
KRAS mutant SYM004 colorectal cancer predicted - resistant detail...
NRAS mutant SYM004 colorectal cancer predicted - resistant detail...
BRAF mutant SYM004 colorectal cancer predicted - resistant detail...
SMAD4 mutant Cetuximab colorectal cancer no benefit detail...
KRAS G13D RAF709 colorectal cancer sensitive detail...
Unknown unknown Nivolumab + Varlilumab colorectal cancer not applicable detail...
BRAF V600E Binimetinib + Cetuximab + Encorafenib colorectal cancer predicted - sensitive detail...
Unknown unknown Fruquintinib colorectal cancer not applicable detail...
Unknown unknown Atezolizumab colorectal cancer no benefit detail...
BRAF mutant HM95573 colorectal cancer sensitive detail...
KRAS mutant HM95573 colorectal cancer sensitive detail...
KDR L840F Sorafenib colorectal cancer resistant detail...
KDR L840F Regorafenib colorectal cancer resistant detail...
KDR R1032Q Cabozantinib colorectal cancer sensitive detail...
KDR R1032Q Lenvatinib colorectal cancer sensitive detail...
NRAS mutant Regorafenib colorectal cancer no benefit detail...
BRAF mutant Regorafenib colorectal cancer no benefit detail...
BRAF V600E Ulixertinib colorectal cancer sensitive detail...
ERBB2 R784G Cetuximab colorectal cancer predicted - resistant detail...
BRAF G596R RMC-4550 colorectal cancer predicted - sensitive detail...
BRAF G596R PTPN11 E76K RMC-4550 colorectal cancer resistant detail...
KRAS G13D RMC-4550 colorectal cancer predicted - resistant detail...
KRAS G12D RMC-4550 colorectal cancer predicted - sensitive detail...
ERBB2 amp Pertuzumab + Trastuzumab colorectal cancer predicted - sensitive detail...
ERBB2 over exp Pertuzumab + Trastuzumab colorectal cancer predicted - sensitive detail...
TP53 R248Q Tanespimycin colorectal cancer sensitive detail...
TP53 del Tanespimycin colorectal cancer decreased response detail...
TP53 R248Q Napabucasin colorectal cancer predicted - sensitive detail...
ERBB2 amp KRAS wild-type Panitumumab colorectal cancer no benefit detail...
ERBB2 amp KRAS wild-type Cetuximab colorectal cancer no benefit detail...
MET del exon14 Crizotinib colorectal cancer sensitive detail...
MET del exon14 Cabozantinib colorectal cancer sensitive detail...
MET del exon14 PHA-665752 colorectal cancer sensitive detail...
MET del exon14 SAIT301 colorectal cancer sensitive detail...
BRAF wild-type KRAS wild-type NRAS wild-type Cetuximab + Irinotecan colorectal cancer predicted - sensitive detail...
Unknown unknown Bevacizumab + trifluridine/tipiracil hydrochloride colorectal cancer not applicable detail...
BRAF V600E NRAS Q61K Panitumumab + Vemurafenib colorectal cancer predicted - resistant detail...
BRAF amp BRAF V600E Panitumumab + Vemurafenib colorectal cancer predicted - resistant detail...
BRAF V47_D380del BRAF V600E Alpelisib + Cetuximab + Encorafenib colorectal cancer predicted - resistant detail...
BRAF V600E NRAS G13R Alpelisib + Cetuximab + Encorafenib colorectal cancer predicted - resistant detail...
BRAF V600E KRAS G12A Alpelisib + Cetuximab + Encorafenib colorectal cancer predicted - resistant detail...
BRAF V600E KRAS amp MET amp Panitumumab + Vemurafenib colorectal cancer predicted - resistant detail...
BRAF V600E NRAS amp Panitumumab + Vemurafenib colorectal cancer predicted - resistant detail...
BRAF V600E NRAS over exp Cetuximab + Vemurafenib colorectal cancer resistant detail...
BRAF V600E KRAS over exp Cetuximab + Vemurafenib colorectal cancer resistant detail...
BRAF V600E NRAS over exp BGB659 + Cetuximab colorectal cancer sensitive detail...
BRAF V600E NRAS G13R BGB659 + Cetuximab colorectal cancer predicted - sensitive detail...
KRAS Q61H Panitumumab + Trametinib colorectal cancer predicted - resistant detail...
BRAF V600E MET over exp Panitumumab + Vemurafenib colorectal cancer resistant detail...
BRAF V600E MET over exp Crizotinib + Vemurafenib colorectal cancer predicted - sensitive detail...
BRAF V600E MET amp Alpelisib + Cetuximab + Encorafenib colorectal cancer predicted - resistant detail...
KRAS exon 2 Cetuximab colorectal cancer resistant detail...
Clinical Trial Phase Therapies Title Recruitment Status
NCT00730158 Phase II Irinotecan KD018 A Phase II Multicenter, Randomized, Placebo Controlled, Double Blinded Clinical Study of KD018 as a Modulator of Irinotecan Chemotherapy in Patients With Metastatic Colorectal Cancer Suspended
NCT00940316 Phase II Irinotecan Erlotinib + Panitumumab Dual Epidermal Growth Factor Receptor Inhibition With Erlotinib and Panitumumab With or Without Chemotherapy for Advanced Colorectal Cancer Active, not recruiting
NCT01006369 Phase II Hydroxychloroquine Bevacizumab + Capecitabine + Oxaliplatin Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin Hydroxychloroquine, Capecitabine, Oxaliplatin, and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer Completed
NCT01037790 Phase II Palbociclib PD 0332991 in Treating Patients With Refractory Solid Tumors Recruiting
NCT01174121 Phase II Pembrolizumab Cyclophosphamide + Fludarabine Aldesleukin Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer Recruiting
NCT01218867 Phase Ib/II Anti-VEGFR2 CAR CD8 lymphocytes Cyclophosphamide Fludarabine Aldesleukin Treating Metastatic Cancer With Anti-VEGFR2 Gene Engineered CD8+ Lymphocytes Completed
NCT01260415 Phase II Panitumumab Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab Fluorouracil + Irinotecan + Leucovorin A Study of Perioperative Chemotherapy Plus Panitumumab in Patients With Colorectal Cancer Liver Metastases Completed
NCT01294826 Phase I Cetuximab + Luminespib Study of AUY922 and Cetuximab in Patients With KRAS Wild-Type Metastatic Colorectal Cancer Completed
NCT01312857 Phase II Panitumumab Fluorouracil + Irinotecan + Leucovorin Floxuridine Study of Hepatic Arterial Infusion With Intravenous Irinotecan, 5FU and Leucovorin With or Without Panitumumab, in Patients With Wild Type KRAS Who Have Resected Hepatic Metastases From Colorectal Cancer Recruiting
NCT01327612 Phase II Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab Ganitumab Bevacizumab Conatumumab Open Label Extension Study of Conatumumab and AMG 479 Active, not recruiting
NCT01340300 Phase II Metformin Exercise and Metformin in Colorectal and Breast Cancer Survivors Completed
NCT01351103 Phase I LGK974 LGK974 + PDR001 A Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands Recruiting
NCT01436656 Phase I Encorafenib A Phase I Study of Oral LGX818 in Adult Patients With Advanced or Metastatic BRAF Mutant Melanoma Active, not recruiting
NCT01543698 Phase Ib/II Binimetinib + Encorafenib Binimetinib + Encorafenib + Ribociclib A Phase Ib/II Study of LGX818 in Combination With MEK162 in Adult Patients With BRAF Dependent Advanced Solid Tumors Active, not recruiting
NCT01569984 Phase II Bevacizumab Radiosensitization of AVASTIN; (Bevacizumab) With Stereotactic Body Radiotherapy for Colorectal Liver Metastasis Completed
NCT01576666 Phase Ib/II Buparlisib + Sonidegib Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors Completed
NCT01587703 Phase I GSK525762 A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of GSK525762 in Subjects With NUT Midline Carcinoma (NMC) and Other Cancers Active, not recruiting
NCT01591421 Phase Ib/II Buparlisib + Panitumumab P13Kinase Inhibitor BKM120 in Combination With Panitumumab in Patients With Metastatic or Advanced RAS-Wild Type Colorectal Cancer. Active, not recruiting
NCT01607905 Phase I Selinexor Safety Study of the Selective Inhibitor of Nuclear Export (SINE) KPT-330 in Patients With Advanced or Metastatic Solid Tumor Cancer Completed
NCT01661972 Phase Ib/II Aflibercept + Capecitabine Phase I/II Study of Capecitabine Plus Aflibercept to Treat Metastatic Colorectal Cancer Completed
NCT01669720 Phase II Aflibercept Adjuvant Aflibercept for Metastatic Colorectal Cancer Terminated
NCT01676714 Phase II Dovitinib Study of Dovitinib and Biomarkers in Advanced Non-Small Cell Lung Cancer or Advanced Colorectal Cancer Completed
NCT01703390 Phase II Cetuximab + Fluorouracil + Leucovorin + Oxaliplatin Cetuximab + Fluorouracil + Irinotecan + Leucovorin Biomarker Directed Treatment in Metastatic Colorectal Cancer Recruiting
NCT01719380 Phase Ib/II Cetuximab + Encorafenib Alpelisib + Cetuximab + Encorafenib Study of LGX818 and Cetuximab or LGX818, BYL719, and Cetuximab in BRAF Mutant Metastatic Colorectal Cancer Completed
NCT01722162 Phase II Bevacizumab + Capecitabine Levocetirizine + Capecitabine + Bevacizumab for Patients With Refractory Colorectal Cancer Completed
NCT01729923 Phase II Capecitabine Celecoxib A Trial of Maintenance ADAPT Therapy With Capecitabine and Celecoxib in Patients With Metastatic Colorectal Cancer Terminated
NCT01750918 Phase II Fluorouracil Dabrafenib + Panitumumab Dabrafenib + Panitumumab + Trametinib Panitumumab + Trametinib BRAF/MEK/EGFR Inhibitor Combination Study in Colorectal Cancer (CRC) Active, not recruiting
NCT01765582 Phase II Capecitabine + Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin Bevacizumab Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin STEAM: A Study of Sequential and Concurrent FOLFOXIRI/Avastin (Bevacizumab) Regimens Versus FOLFOX/Avastin in First-Line in Patients With Metastatic Colorectal Cancer Terminated
NCT01776307 Phase II Cetuximab + Napabucasin Capecitabine + Napabucasin Napabucasin + Panitumumab A Study of BBI608 in Adult Patients With Advanced Colorectal Cancer Active, not recruiting
NCT01871311 Phase I Cetuximab + Nilotinib A Phase I Study of the BCR-ABL Tyrosine Kinase Inhibitor Nilontinib and Cetuximab in Patients With Solid Tumors That Can be Treated With Cetuximab Terminated
NCT01874860 Phase I Doxycycline Skin Rash Study Before Chemotherapy in Colorectal & Head and Neck Cancer Patients Recruiting
NCT01876511 Phase II Pembrolizumab Phase 2 Study of MK-3475 in Patients With Microsatellite Unstable (MSI) Tumors Recruiting
NCT01888965 Phase II Dovitinib Maintenance Dovitinib for Colorectal and Pancreas Cancer Terminated
NCT01923337 Phase I Alisertib + Irinotecan Irinotecan and Alisertib in Treating Patients With Advanced Solid Tumors or Colorectal Cancer Completed
NCT01927341 Phase Ib/II Binimetinib Panitumumab Phase Ib/II Study of Efficacy and Safety of MEK162 and Panitumumab, in Adult mCRC Patients With Mutant or Wild-type RAS Tumors Completed
NCT01937715 Phase II Bevacizumab Gedatolisib Fluorouracil + Irinotecan + Leucovorin A Study Of PF-05212384 Plus FOLFIRI Versus Bevacizumab Plus FOLFIRI In Metastatic Colorectal Cancer Terminated
NCT01939223 Phase III Regorafenib COlorectal Cancer Treated With Adjuvant Regorafenib Versus Placebo After Curative Treatment of Liver Metastases in a Randomized, Double-blind, Placebo?Controlled Phase-III STudy (COAST) Terminated
NCT01960023 Phase Ib/II Cetuximab + Neratinib Safety and Efficacy Study of Neratinib and Cetuximab to Treat Patients With Quadruple Wild-Type Metastatic Colorectal Cancer Withdrawn
NCT01966445 Phase I GSK2849330 Dose Escalation Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of GSK2849330 in Subjects With Advanced Her3-Positive Solid Tumors Completed
NCT01968109 Phase I Nivolumab + Relatlimab Relatlimab Safety Study of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid Tumors Recruiting
NCT01974258 Phase I Onartuzumab + Vemurafenib Cobimetinib + Onartuzumab Cobimetinib + Onartuzumab + Vemurafenib Safety, Tolerability, and Pharmacokinetics of Onartuzumab Combined With Vemurafenib and/or Cobimetinib in Cancer Patients Withdrawn
NCT01988896 Phase I Atezolizumab + Cobimetinib A Phase 1b Study of MPDL3280A (an Engineered Anti-PDL1 Antibody) in Combination With Cobimetinib in Patients With Locally Advanced or Metastatic Solid Tumors Active, not recruiting
NCT02004106 Phase I RO6895882 A Study of RO6895882 in Patients With Advanced and/or Metastatic Solid Tumors Completed
NCT02009449 Phase I Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab Pembrolizumab Carboplatin Gemcitabine Docetaxel Pazopanib Capecitabine Paclitaxel Cisplatin Pegilodecakin Nab-paclitaxel A Phase 1 Study of AM0010 in Patients With Advanced Solid Tumors Active, not recruiting
NCT02025803 Phase I Capecitabine + TAS-114 A Safety, Tolerability and Pharmacokinetic Study of TAS-114 in Combination With Capecitabine in Patients With Advanced Solid Tumors Completed
NCT02038699 Phase Ib/II ONC201 A First-in-man Phase I/II Study of Oral ONC201 in Patients With Advanced Cancer Withdrawn
NCT02041481 Phase I Binimetinib + Fluorouracil + Leucovorin + Oxaliplatin MEK Inhibitor MEK162 in Combination With Leucovorin Calcium, Fluorouracil, and Oxaliplatin in Treating Patients With Advanced Metastatic Colorectal Cancer Completed
NCT02060188 Phase Ib/II Nivolumab Ipilimumab A Study of Nivolumab and Nivolumab Plus Ipilimumab in Recurrent and Metastatic Colon Cancer (CheckMate 142) Active, not recruiting
NCT02083653 Phase II SYM004 Fluorouracil Capecitabine Sym004 vs Standard of Care in Subjects With Metastatic Colorectal Cancer Completed
NCT02110082 Phase I Cetuximab + Urelumab Combination Study of Urelumab and Cetuximab in Patients With Advanced/Metastatic Colorectal Cancer or Advanced/Metastatic Head and Neck Cancer Completed
NCT02122809 Phase I Chiauranib Phase I Study of Chiauranib in Patients With Advanced Solid Tumors Completed
NCT02124148 Phase I Cisplatin + Prexasertib Cetuximab + Prexasertib Pemetrexed + Prexasertib LY3023414 + Prexasertib Fluorouracil + Leucovorin + Prexasertib A Study of LY2606368 With Cisplatin or Cetuximab in Participants With Advanced Cancer Active, not recruiting
NCT02141295 Phase II Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin RO5520985 Bevacizumab + Fluorouracil + Leucovorin Fluorouracil + Leucovorin + RO5520985 Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab A Study Comparing the Efficacy and Safety of RO5520985 and FOLFOX With Bevacizumab and FOLFOX in Patients With Untreated Metastatic Colorectal Cancer (McCAVE) Completed
NCT02168777 Phase Ib/II Refametinib + Regorafenib Refametinib Refametinib (BAY86-9766) in Combination With Regorafenib (Stivarga, BAY73-4506) in Patients With Advanced or Metastatic Cancer Terminated
NCT02187848 Phase Ib/II SAR408701 Evaluation of SAR408701 in Patients With Advanced Solid Tumors Recruiting
NCT02199223 Phase I Panitumumab + Regorafenib Regorafenib + Panitumumab Terminated
NCT02205398 Phase Ib/II Capmatinib + Cetuximab Study of Safety and Efficacy of INC280 and Cetuximab, in Adult c-MET Positive mCRC and HNSCC Patients After Progression on Cetuximab or Panitumumab Therapy Terminated
NCT02227667 Phase II Durvalumab Evaluate the Efficacy of MEDI4736 in Immunological Subsets of Advanced Colorectal Cancer Active, not recruiting
NCT02260440 Phase II Azacitidine + Pembrolizumab A Phase 2 Study of MK-3475 in Combination With Azacitidine in Subjects With Chemo-refractory Metastatic Colorectal Cancer Active, not recruiting
NCT02268825 Phase Ib/II Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab Pembrolizumab Phase I/IIA Study MK-3475 With Chemotherapy in Patients With Advanced GI Cancers Terminated
NCT02277093 Phase II Pacritinib Pacritinib to Inhibit JAK/STAT Signaling in Refractory Colorectal Cancer Terminated
NCT02278133 Phase Ib/II Cetuximab + Encorafenib + LGK974 Study of WNT974 in Combination With LGX818 and Cetuximab in Patients With BRAF-mutant Metastatic Colorectal Cancer (mCRC) and Wnt Pathway Mutations Completed
NCT02279433 Phase I DS6051b A First-in-human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of DS-6051b Active, not recruiting
NCT02287025 FDA approved Regorafenib A Phase 4 Study of Regorafenib in Metastatic Colorectal Cancer - Does Educating Physicians Change Patient Out Comes? Terminated
NCT02298959 Phase I Aflibercept + Pembrolizumab Pembrolizumab and Ziv-aflibercept in Treating Patients With Advanced Solid Tumors Recruiting
NCT02310464 Phase I OBI-821 + OBI-833 Trial of Active Immunotherapy With OBI-833 (Globo H-CRM197) in Advanced/Metastatic Gastric, Lung, Colorectal or Breast Cancer Subjects Recruiting
NCT02316340 Phase II Vorinostat Hydroxychloroquine Regorafenib Vorinostat Plus Hydroxychloroquine Versus Regorafenib in Colorectal Cancer Recruiting
NCT02318901 Phase Ib/II Ado-trastuzumab emtansine + Pembrolizumab Pembrolizumab + Trastuzumab Cetuximab + Pembrolizumab Pembrolizumab and Monoclonal Antibody Therapy in Advanced Cancer Terminated
NCT02327078 Phase Ib/II Epacadostat + Nivolumab A Study of the Safety, Tolerability, and Efficacy of INCB24360 Administered in Combination With Nivolumab in Select Advanced Cancers Active, not recruiting
NCT02335918 Phase Ib/II Nivolumab + Varlilumab A Dose Escalation and Cohort Expansion Study of Anti-CD27 (Varlilumab) and Anti-PD-1 (Nivolumab) in Advanced Refractory Solid Tumors Completed
NCT02346955 Phase I CM-24 CM-24 + Pembrolizumab Study of CM-24 (MK-6018) Alone and In Combination With Pembrolizumab (MK-3475) in Participants With Selected Advanced or Recurrent Malignancies (MK-6018-001) Terminated
NCT02365662 Phase I ABBV-221 A Study Evaluating Safety and Pharmacokinetics of ABBV-221 in Subjects With Advanced Solid Tumor Types Likely to Exhibit Elevated Levels of Epidermal Growth Factor Receptor Terminated
NCT02386826 Phase I Bevacizumab + Capmatinib INC280 Combined With Bevacizumab to Evaluate Glioblastoma Multiforme, Metastatic Colorectal Cancer, and Metastatic Renal Cell Carcinoma Patients Recruiting
NCT02399943 Phase II Panitumumab + Trametinib A Trial of Trametinib and Panitumumab in RAS/RAF Wild Type Advanced Colorectal Cancer Recruiting
NCT02402036 Phase II Regorafenib A Biomarker Study in Patients Getting Regorafenib for Metastatic Colorectal Cancer Terminated
NCT02425683 Phase II Regorafenib Study of Colorectal Cancer Patients (Stage IIIC) With Either Regorafenib or Standard of Care (No Treatment) After Adjuvant FOLFOX Terminated
NCT02437071 Phase II Pembrolizumab Assess the Efficacy of Pembrolizumab Plus Radiotherapy or Ablation in Metastatic Colorectal Cancer Patients Active, not recruiting
NCT02444793 Phase I Mogamulizumab + Utomilumab A Study of PF-05082566 In Combination With Mogamulizumab In Patients With Advanced Solid Tumors Terminated
NCT02448810 Phase II Fluorouracil + Leucovorin Imalumab Panitumumab Phase 2a Study of BAX69 and 5-FU/Leucovorin or Panitumumab Versus Standard of Care in Subjects With Metastatic Colorectal Cancer Terminated
NCT02460198 Phase II Pembrolizumab Study of Pembrolizumab (MK-3475) as Monotherapy in Participants With Previously-Treated Locally Advanced Unresectable or Metastatic Colorectal Cancer (MK-3475-164/KEYNOTE-164) Active, not recruiting
NCT02460224 Phase Ib/II LAG525 PDR001 Safety and Efficay of LAG525 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies Active, not recruiting
NCT02512172 Phase I Azacitidine + Pembrolizumab Pembrolizumab + Romidepsin Azacitidine + Pembrolizumab + Romidepsin A Study of Enhancing Response to MK-3475 in Advanced Colorectal Cancer Active, not recruiting
NCT02516553 Phase I BI 894999 BI 894999 First in Human Dose Finding Study in Advanced Malignancies Recruiting
NCT02526017 Phase I Cabiralizumab Nivolumab Study of FPA008 in Combination With Nivolumab in Patients With Selected Advance Cancers Active, not recruiting
NCT02528357 Phase I GSK3174998 Pembrolizumab GSK3174998 Alone or With Pembrolizumab in Subjects With Advanced Solid Tumors Recruiting
NCT02538627 Phase I Seribantumab MM-151 Phase 1 Combination Study of MM-151 and MM-121 Terminated
NCT02540291 Phase I E7046 Study of E7046 in Subjects With Selected Advanced Malignancies Terminated
NCT02559024 Phase I MEDI6469 Anti-OX40 Antibody (MEDI6469) in Patients With Metastatic Colorectal Cancer Active, not recruiting
NCT02559492 Phase I Epacadostat + Itacitinib Itacitinib + Parsaclisib INCB039110 Combined With INCB024360 and/or INCB039110 Combined With INCB050465 in Advanced Solid Tumors Active, not recruiting
NCT02563002 Phase III Fluorouracil + Leucovorin + Oxaliplatin Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin Fluorouracil + Irinotecan + Leucovorin Cetuximab + Fluorouracil + Irinotecan + Leucovorin Bevacizumab + Fluorouracil + Irinotecan + Leucovorin Cetuximab + Fluorouracil + Leucovorin + Oxaliplatin Pembrolizumab Study of Pembrolizumab (MK-3475) vs Standard Therapy in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Carcinoma (MK-3475-177/KEYNOTE-177) Active, not recruiting
NCT02568046 Phase Ib/II Fluorouracil + Irinotecan + Leucovorin + SYM004 Sym004 in Combination With FOLFIRI in Metastatic Colorectal Cancer Patients Terminated
NCT02568267 Phase II Entrectinib Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK1/2/3, ROS1, or ALK Gene Rearrangements (STARTRK-2) Recruiting
NCT02573220 Phase I Cetuximab + Fluorouracil + Irinotecan + Leucovorin Irinotecan Hydrochloride With FOLFIRI and Cetuximab as First-Line Therapy in Treating Patients With RAS Wild-Type Colorectal Cancer Withdrawn
NCT02575781 Phase I SAR428926 A Study of SAR428926 in Patients With Advanced Solid Tumors Completed
NCT02576431 Phase II Larotrectinib Study of LOXO-101 in Subjects With NTRK Fusion Positive Solid Tumors Recruiting
NCT02576665 Phase I Toca 511 + Toca FC A Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC in Subjects With Solid Tumors (Toca6) Active, not recruiting
NCT02599324 Phase Ib/II Docetaxel Ibrutinib Everolimus Paclitaxel Cetuximab A Study to Evaluate Ibrutinib Combination Therapy in Patients With Selected Gastrointestinal and Genitourinary Tumors Recruiting
NCT02600949 Phase I Pembrolizumab Peptide Vaccine in Advanced Pancreatic Ductal Adenocarcinoma or Colorectal Adenocarcinoma Active, not recruiting
NCT02605044 Phase III Masitinib Fluorouracil + Irinotecan + Leucovorin Study to Compare the Efficacy and Safety of Masitinib in Combination With FOLFIRI to Placebo in Combination With FOLFIRI in Second Line Treatment of Patients With Metastatic Colorectal Cancer Terminated
NCT02613650 Phase I Binimetinib + Fluorouracil + Irinotecan + Leucovorin A Trial of FOLFIRI With MEK162 in Patients With Advanced KRAS Positive Metastatic Colorectal Cancers Recruiting
NCT02630420 Phase I Cetuximab + Savolitinib Cetuximab and Savolitinib Treatment of Ras Wild-Type Colorectal Cancer Withdrawn
NCT02632448 Phase Ib/II Gemcitabine + LY2880070 LY2880070 A Study of LY2880070 in Patients With Advanced or Metastatic Cancer Recruiting
NCT02636036 Phase I Enadenotucirev + Pembrolizumab Study of Enadenotucirev and Pembrolizumab in Subjects With Metastatic or Advanced Epithelial Tumors Recruiting
NCT02646748 Phase I Parsaclisib Pembrolizumab Itacitinib Pembrolizumab Combined With INCB039110 and/or Pembrolizumab Combined With INCB050465 in Advanced Solid Tumors Recruiting
NCT02654639 Phase II Bevacizumab + trifluridine/tipiracil hydrochloride Ph 2 Study of TAS-102 / Bevacizumab Maintenance Therapy Post Induction Chemotherapy in Metastatic Colorectal Cancer Terminated
NCT02655822 Phase I Atezolizumab CPI-444 Phase 1/1b Study to Evaluate the Safety and Tolerability of CPI-444 Alone and in Combination With Atezolizumab in Advanced Cancers Recruiting
NCT02665416 Phase I RO5520985 + RO7009789 Study Evaluating the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD), and Therapeutic Activity of RO7009789 With Vanucizumab in Metastatic Solid Tumors Recruiting
NCT02671955 Phase I JNJ-61610588 A Study of Safety, Pharmacokinetics, Pharmacodynamics of JNJ-61610588 in Participants With Advanced Cancer Terminated
NCT02693535 Phase II Cobimetinib + Vemurafenib Regorafenib Vismodegib Bosutinib Palbociclib Cetuximab Axitinib Pembrolizumab Temsirolimus Dasatinib Pertuzumab + Trastuzumab Crizotinib Sunitinib Olaparib Erlotinib TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer Recruiting
NCT02703571 Phase Ib/II Ribociclib + Trametinib Study of Safety and Efficacy of Ribociclib and Trametinib in Patients With Metastatic or Advanced Solid Tumors Recruiting
NCT02713373 Phase Ib/II Cetuximab + Pembrolizumab Cetuximab and Pembrolizumab in Treating Patients With Colorectal Cancer That is Metastatic or Cannot Be Removed by Surgery Recruiting
NCT02713529 Phase Ib/II AMG 820 + Pembrolizumab Safety Study of AMG 820 and Pembrolizumab Combination in Select Advanced Solid Tumor Cancer Active, not recruiting
NCT02723955 Phase I GSK3359609 GSK3359609 + Pembrolizumab Dose Escalation and Expansion Study of GSK3359609 in Subjects With Selected Advanced Solid Tumors (INDUCE-1) Recruiting
NCT02745769 Phase I Merestinib + Ramucirumab Abemaciclib + Ramucirumab A Study in Advanced Cancers Using Ramucirumab (LY3009806) and Other Targeted Agents Completed
NCT02753127 Phase III Fluorouracil + Irinotecan + Leucovorin Napabucasin A Study of Napabucasin (BBI-608) in Combination With FOLFIRI in Adult Patients With Previously Treated Metastatic Colorectal Cancer (CanStem303C) Active, not recruiting
NCT02754856 Phase I Bevacizumab + Durvalumab + Fluorouracil + Leucovorin + Oxaliplatin + Tremelimumab Tremelimumab (Anti-CTLA-4) Plus MEDI4736 (Anti-PD-L1) in Resectable Colorectal Cancer Liver Metastases. Recruiting
NCT02760797 Phase I Emactuzumab + RO7009789 A Study of Emactuzumab and RO7009789 Administered in Combination in Participants With Advanced Solid Tumors Completed
NCT02785068 Phase I Fluorouracil + Irinotecan + Leucovorin + MM-151 Evaluation of MM-151 + Nal-IRI + 5-FU + Leucovorin in RAS/RAF Wild-type Metastatic Colorectal Cancer Withdrawn
NCT02811497 Phase II Azacitidine + Durvalumab Study of Azacitidine and Durvalumab in Advanced Solid Tumors (METADUR) Recruiting
NCT02837263 Phase I Pembrolizumab PI Pembro in Combination With Stereotactic Body Radiotherapy for Liver Metastatic Colorectal Cancer Recruiting
NCT02857270 Phase I LY3214996 Gemcitabine + LY3214996 + Nab-paclitaxel LY3214996 + Midazolam Abemaciclib + LY3214996 A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic Cancer Recruiting
NCT02870920 Phase II Durvalumab + Tremelimumab Durvalumab and Tremelimumab and Best Supportive Care vs Best Supportive Care Alone in Patients With Advanced Colorectal Adenocarcinoma Refractory to Standard Therapies Active, not recruiting
NCT02873195 Phase II Bevacizumab + Capecitabine Atezolizumab + Bevacizumab + Capecitabine Capecitabine and Bevacizumab With or Without Atezolizumab in Treating Patients With Refractory Metastatic Colorectal Cancer Active, not recruiting
NCT02880371 Phase Ib/II ARRY-382 + Pembrolizumab A Study of ARRY-382 in Combination With Pembrolizumab for the Treatment of Patients With Advanced Solid Tumors Active, not recruiting
NCT02888743 Phase II Durvalumab + Tremelimumab Durvalumab and Tremelimumab With or Without High or Low-Dose Radiation Therapy in Treating Patients With Metastatic Colorectal or Non-small Cell Lung Cancer Active, not recruiting
NCT02890069 Phase I LCL161 + PDR001 Everolimus + PDR001 Panobinostat + PDR001 A Study of PDR001 in Combination With LCL161, Everolimus or Panobinostat Recruiting
NCT02900664 Phase I Nazartinib + PDR001 CJM112 + PDR001 PDR001 + Trametinib Canakinumab + PDR001 A Study of PDR001 in Combination With CJM112, EGF816, Ilaris (Canakinumab) or Mekinist (Trametinib) Recruiting
NCT02906059 Phase I Adavosertib + Irinotecan Study of Irinotecan and AZD1775, a Selective Wee 1 Inhibitor, in RAS or BRAF Mutated, Second-line Metastatic Colorectal Cancer Recruiting
NCT02928224 Phase III Cetuximab + Encorafenib Binimetinib + Cetuximab + Encorafenib Cetuximab + Irinotecan Cetuximab + Fluorouracil + Irinotecan + Leucovorin Study of Encorafenib + Cetuximab Plus or Minus Binimetinib vs. Irinotecan/Cetuximab or Infusional 5-Fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab With a Safety Lead-in of Encorafenib + Binimetinib + Cetuximab in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer (BEACON CRC) Active, not recruiting
NCT02947165 Phase I NIS793 + PDR001 NIS793 Phase I/Ib Study of NIS793 in Combination With PDR001 in Patients With Advanced Malignancies. Recruiting
NCT02953782 Phase Ib/II Cetuximab + Hu5F9-G4 Trial of Hu5F9-G4 in Combination With Cetuximab in Patients With Solid Tumors and Advanced Colorectal Cancer Recruiting
NCT02959437 Phase Ib/II Azacitidine + Epacadostat + Pembrolizumab Azacitidine Combined With Pembrolizumab and Epacadostat in Subjects With Advanced Solid Tumors (ECHO-206) Active, not recruiting
NCT02960594 Phase I INO-1400 + INO-9012 INO-1400 hTERT Immunotherapy Alone or in Combination With IL-12 DNA Followed by Electroporation in Adults With Solid Tumors at High Risk of Relapse Completed
NCT02961283 Phase I ASN003 Study of ASN003 in Subjects With Advanced Solid Tumors Active, not recruiting
NCT02963831 Phase Ib/II Durvalumab + ONCOS-102 A Phase 1/2 Study to Investigate the Safety, Biologic and Anti-tumor Activity of ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies Recruiting
NCT02965417 Phase II SYM004 Sym004 in Metastatic Colorectal Cancer and ECD-EGFR Patients Withdrawn
NCT02981524 Phase II Cyclophosphamide + GVAX colorectal cancer vaccine + Pembrolizumab Phase 2 Study of GVAX (With CY) and Pembrolizumab in MMR-p Advanced Colorectal Cancer Active, not recruiting
NCT02983578 Phase II AZD9150 + Durvalumab AZD9150 With MEDI4736 in Patients With Advanced Pancreatic, Non-Small Lung and Colorectal Cancer Recruiting
NCT02991196 Phase I DS-8273a + Nivolumab Antibody DS-8273a Administered in Combination With Nivolumab in Subjects With Advanced Colorectal Cancer Terminated
NCT03005002 Phase I Durvalumab + Tremelimumab Durvalumab and Tremelimumab in Treating Patients With Microsatellite Stable Metastatic Colorectal Cancer to the Liver Active, not recruiting
NCT03018405 Phase I NKR-2 cells A Dose Escalation Phase I Study to Assess the Safety and Clinical Activity of Multiple Cancer Indications (THINK) Recruiting
NCT03031691 Phase I Brontictuzumab + Trifluridine A Study of Brontictuzumab With Chemotherapy for Subjects With Previously Treated Metastatic Colorectal Cancer Completed
NCT03035279 Phase I SC-006 A Study of SC-006 in Subjects With Advanced Cancer Completed
NCT03050814 Phase II Bevacizumab + Capecitabine + Fluorouracil + Leucovorin + Oxaliplatin Ad-CEA vaccine + Avelumab + Bevacizumab + Capecitabine + Fluorouracil + Leucovorin + Oxaliplatin Standard of Care Alone or in Combination With Ad-CEA Vaccine and Avelumab in People With Previously Untreated Metastatic Colorectal Cancer Recruiting
NCT03087591 Phase I APN401 APN401 in Treating Patients With Recurrent or Metastatic Pancreatic Cancer, Colorectal Cancer, or Other Solid Tumors That Cannot Be Removed by Surgery Recruiting
NCT03099486 Phase II Fluorouracil + Leucovorin + Regorafenib Regorafenib Plus 5-Fluorouracil/Leucovorin Beyond Progression in mCRC Recruiting
NCT03122509 Phase II Durvalumab + Tremelimumab A Clinical Trial of Durvalumab and Tremelimumab, Administered With Radiation Therapy or Ablation in Patients With Colorectal Cancer Recruiting
NCT03184870 Phase Ib/II BMS-813160 + Fluorouracil + Irinotecan + Leucovorin BMS-813160 + Nivolumab BMS-813160 + Gemcitabine + Nab-paclitaxel BMS-813160 A Study of BMS-813160 in Combination With Chemotherapy or Nivolumab in Patients With Advanced Solid Tumors Recruiting
NCT03188965 Phase I BAY1895344 First-in-human Study of ATR Inhibitor BAY1895344 in Patients With Advanced Solid Tumors and Lymphomas Recruiting
NCT03189030 Phase I pLADD Study of Personalized Immunotherapy in Adults With Metastatic Colorectal Cancer Active, not recruiting
NCT03203525 Phase I Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin Bevacizumab + Doxorubicin + Temsirolimus Study of the NovoTTF-100L System to Enhance Antitumor Activity in Patients With Predominant Hepatic Metastatic Cancer Not yet recruiting
NCT03206073 Phase Ib/II Durvalumab + Tremelimumab Durvalumab A Phase I/II Study of Pexa-Vec Oncolytic Virus in Combination With Immune Checkpoint Inhibition in Refractory Colorectal Cancer Recruiting
NCT03215264 Phase Ib/II Entinostat + Hydroxychloroquine + Regorafenib Phase I/II Trial of Regorafenib, Hydroxychloroquine, and Entinostat in Metastatic Colorectal Cancer Recruiting
NCT03223779 Phase Ib/II Trifluridine Study of TAS-102 Plus Radiation Therapy for the Treatment of the Liver in Patients With Hepatic Metastases From Colorectal Cancer Recruiting
NCT03234712 Phase I ABBV-321 A Study Evaluating the Safety, Pharmacokinetics, and Anti-tumor Activity of ABBV-321 in Subjects With Advanced Solid Tumors Associated With Overexpression of the Epidermal Growth Factor Receptor (EGFR) or Its Ligands Recruiting
NCT03239145 Phase I Pembrolizumab + Trebananib Phase Ib Study to Test the Safety and Potential Synergy of Pembrolizumab (Anti-PD-1) and AMG386 (Angiopoietin-2 (Ang-2) in Patients With Advanced Solid Tumor Recruiting
NCT03256344 Phase I Atezolizumab + Talimogene laherparepvec A Safety Study of Talimogene Laherparepvec Combined With Atezolizumab for Triple Negative Breast Cancer and Colorectal Cancer With Liver Metastases Recruiting
NCT03259867 Phase II Nivolumab Pembrolizumab Combination of TATE and PD-1 Inhibitor in Liver Cancer Recruiting
NCT03263429 Phase Ib/II CB-839 + Irinotecan + Panitumumab Novel PET/CT Imaging Biomarkers of CB-839 in Combination With Panitumumab and Irinotecan in Patients With Metastatic and Refractory RAS Wildtype Colorectal Cancer Recruiting
NCT03265080 Phase I ADXS-NEO Expressing Personalized Tumor Antigens Study Recruiting
NCT03271047 Phase Ib/II Binimetinib + Ipilimumab + Nivolumab Binimetinib + Nivolumab Study of Binimetinib + Nivolumab Plus or Minus Ipilimumab in Patients With Previously Treated Microsatellite-stable (MSS) Metastatic Colorectal Cancer With RAS Mutation Active, not recruiting
NCT03289962 Phase I RO7198457 Atezolizumab + RO7198457 A Study of RO7198457 (Personalized Cancer Vaccine [PCV]) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors Recruiting
NCT03290937 Phase I Cetuximab + Irinotecan + Utomilumab Clinical Trial Evaluating the Safety and Response With PF-05082566, Cetuximab and Irinotecan in Patients With Advanced Colorectal Cancer Recruiting
NCT03307603 Phase Ib/II Nivolumab + Yttrium-90 Yttrium-90 Radioembolization + Nivolumab for Liver + Extra-hepatic Metastases From Colorectal Cancer Withdrawn
NCT03313778 Phase I mRNA-4157 + Pembrolizumab mRNA-4157 Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects With Resected Solid Tumors and in Combination With Pembrolizumab in Subjects With Unresectable Solid Tumors (KEYNOTE-603) Recruiting
NCT03319459 Phase I FATE-NK100 FATE-NK100 + Trastuzumab Cetuximab + FATE-NK100 FATE-NK100 as Monotherapy and in Combination With Monoclonal Antibody in Subjects With Advanced Solid Tumors Recruiting
NCT03329950 Phase I CDX-1140 + CDX-301 CDX-1140 A Study of CDX-1140 as Monotherapy or in Combination in Patients With Advanced Solid Tumors Recruiting
NCT03340558 Phase II Atezolizumab Atezolizumab + Cobimetinib Atezolizumab Monotherapy vs Atezolizumab Plus Cobimetinib in Liver Metastases From Colorectal Cancer (ATELIER) Withdrawn
NCT03361228 Phase Ib/II Epacadostat + INCB001158 Epacadostat + INCB001158 + Pembrolizumab A Study to Evaluate the Safety, Tolerability, and Antitumor Activity of INCB001158 Plus Epacadostat, With or Without Pembrolizumab, in Advanced Solid Tumors Completed
NCT03363776 Phase Ib/II BMS-986277 BMS-986277 + Nivolumab An Immuno-Therapy Study of Experimental Medication BMS-986277 Given Alone and in Combination With Nivolumab in Epithelial Cancers Recruiting
NCT03374254 Phase I Fluorouracil + Irinotecan + Leucovorin + Pembrolizumab Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab Binimetinib + Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab Binimetinib + Fluorouracil + Irinotecan + Leucovorin + Pembrolizumab Safety and Efficacy of Pembrolizumab (MK-3475) Plus Binimetinib Alone or Pembrolizumab Plus Chemotherapy With or Without Binimetinib in Metastatic Colorectal Cancer (mCRC) Participants (MK-3475-651) Recruiting
NCT03377361 Phase Ib/II Ipilimumab + Nivolumab Ipilimumab + Nivolumab + Trametinib An Investigational Immuno-therapy Study Of Nivolumab In Combination With Trametinib With Or Without Ipilimumab In Patients With Previously Treated Cancer of the Colon or Rectum That Has Spread Recruiting
NCT03391232 Phase I PolyPEPI1018 Safety and Immunogenicity of PolyPEPI1018 Vaccine in the Treatment of Metastatic Colorectal Cancer (OBERTO) Recruiting
NCT03403634 Phase I Celecoxib + Interferon alpha-2b + Rintatolimod Celecoxib, Recombinant Interferon Alfa-2b, and Rintatolimod in Treating Patients With Colorectal Cancer Metastatic to the Liver Recruiting
NCT03407976 Phase Ib/II Apatinib + Pembrolizumab Apatinib With Pembrolizumab in Previously Treated Advanced Malignancies Recruiting
NCT03410927 Phase Ib/II TAS0728 A Study of TAS0728 in Patients With Solid Tumors With HER2 or HER3 Abnormalities Recruiting
NCT03414983 Phase II Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin Bevacizumab + Fluorouracil + Leucovorin + Nivolumab + Oxaliplatin An Investigational Immunotherapy Study of Nivolumab With Standard of Care Therapy vs Standard of Care Therapy for First-Line Treatment of Colorectal Cancer That Has Spread (CheckMate 9X8) Recruiting
NCT03428126 Phase II Durvalumab + Trametinib Study of Durvalumab (MEDI4736) (Anti-PD-L1) and Trametinib (MEKi) in MSS Metastatic Colon Cancer Enrolling by invitation
NCT03428958 Phase I A Safety Study of NUC-3373 in Combination With Standard Agents Used in Colorectal Cancer Treatment Recruiting
NCT03435640 Phase Ib/II NKTR-214 + NKTR-262 Nivolumab + NKTR-214 + NKTR-262 A Study of NKTR-262 in Combination With NKTR-214 and With NKTR-214 Plus Nivolumab in Patients With Locally Advanced or Metastatic Solid Tumor Malignancies Recruiting
NCT03439462 Phase Ib/II Bevacizumab + Fluorouracil + Leucovorin + Nab-Rapamycin + Oxaliplatin ABI-009 (Nab-rapamycin) in Combination With FOLFOX and Bevacizumab as First-line Therapy in Patients With Advanced or Metastatic Colorectal Cancer Recruiting
NCT03446157 Phase II Cetuximab + Palbociclib Palbociclib and Cetuximab in Metastatic Colorectal Cancer Recruiting
NCT03454451 Phase I CPI-006 CPI-006 + Pembrolizumab CPI-006 + CPI-444 CPI-006 Alone and in Combination With CPI-444 and With Pembrolizumab for Patients With Advanced Cancers Recruiting
NCT03457896 Phase II Cetuximab + Neratinib Neratinib + Trastuzumab Study of Neratinib +Trastuzumab or Neratinib + Cetuximab in Patients With KRAS/NRAS/BRAF/PIK3CA Wild-Type Metastatic Colorectal Cancer by HER2 Status Recruiting
NCT03473925 Phase II Navarixin + Pembrolizumab Efficacy and Safety Study of Navarixin (MK-7123) in Combination With Pembrolizumab (MK-3475) in Adults With Selected Advanced/Metastatic Solid Tumors (MK-7123-034) Recruiting
NCT03476681 Phase I NEO-201 QUILT-3.017: Study of NEO-201 in Solid Tumors Recruiting
NCT03485209 Phase II Tisotumab Vedotin Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid Tumors Recruiting
NCT03526835 Phase I MCLA-158 A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors Recruiting
NCT03531632 Phase Ib/II MGA012 + MGD007 MGD007 Combined With MGA012 in Relapsed/Refractory Metastatic Colorectal Cancer Recruiting
NCT03538028 Phase I INCAGN02385 A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies Recruiting
NCT03547999 Phase II Fluorouracil + Leucovorin + Nivolumab + Oxaliplatin CV301 + Fluorouracil + Leucovorin + Nivolumab + Oxaliplatin A Trial of Perioperative CV301 Vaccination in Combination With Nivolumab and Systemic Chemotherapy for Metastatic CRC Recruiting
NCT03549338 Phase II Modotuximab Futuximab SYM004 Sym004 Versus Futuximab or Modotuximab in Patients With mCRC Terminated
NCT03555149 Phase Ib/II Atezolizumab Atezolizumab + Isatuximab Atezolizumab + Bevacizumab + PGG beta-glucan A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Metastatic Colorectal Cancer (Morpheus-CRC) Recruiting
NCT03563157 Phase Ib/II Aldoxorubicin + ALT-803 + Avelumab + Capecitabine + Cetuximab + Cyclophosphamide + ETBX-011 + ETBX-021 + ETBX-051 + ETBX-061 + Fluorouracil + GI-4000 + GI-6207 + GI-6301 + haNK cells + Leucovorin + Nab-paclitaxel + Oxaliplatin + Regorafenib + Trastuzumab Regorafenib QUILT 3.071: NANT Colorectal Cancer (CRC) Vaccine Recruiting
NCT03568539 Phase Ib/II Sintilimab IBI308 in Subjects With Advanced/Metastatic Solid Malignancies Recruiting
NCT03596372 Phase I BAY1834942 Study of BAY1834942 in Patients With Solid Tumors Recruiting
NCT03628677 Phase I AB154 AB154 + GLS-010 A Study to Evaluate the Safety and Tolerability of AB154 in Participants With Advanced Malignancies Recruiting
NCT03629756 Phase I AB928 + GLS-010 A Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Advanced Malignancies Recruiting
NCT03631407 Phase II Pembrolizumab + Vicriviroc Safety and Efficacy of Vicriviroc (MK-7690) in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Microsatellite Stable (MSS) Colorectal Cancer (CRC) (MK-7690-046) Recruiting
NCT03639714 Phase Ib/II GRT-C901 + GRT-R902 + Ipilimumab + Nivolumab A Study of a Personalized Neoantigen Cancer Vaccine Recruiting
NCT03656718 Phase Ib/II Nivolumab Nivolumab + rHuPH20 A Study of Subcutaneous Nivolumab Monotherapy With or Without Recombinant Human Hyaluronidase PH20 (rHuPH20) Recruiting
NCT03657641 Phase Ib/II Pembrolizumab + Regorafenib Regorafenib and Pembrolizumab in Treating Participants With Advanced or Metastatic Colorectal Cancer Not yet recruiting
NCT03658772 Phase I Grapiprant + Pembrolizumab Grapiprant and Pembrolizumab in Patients With Advanced or Progressive MSS Colorectal Cancer Recruiting
NCT03661632 Phase Ib/II BMS-986310 + Nivolumab Nivolumab An Investigational Immunotherapy Study of BMS-986310 Administered Alone and in Combination With Nivolumab in Patients With Advanced Solid Tumors Recruiting
NCT03668431 Phase II Dabrafenib + PDR001 + Trametinib Dabrafenib + Trametinib + PDR001 In Colorectal Cancer Recruiting
NCT03693170 Phase II Binimetinib + Cetuximab + Encorafenib encorAfenib, biNimetinib and Cetuximab in Subjects witH previOusly Untreated BRAF-mutant ColoRectal Cancer (ANCHOR-CRC) Recruiting
NCT03700294 Phase I ADCT-601 Safety, Tolerability, Pharmacokinetics, and Antitumor Study of ADCT-601 to Treat Advanced Solid Tumors Recruiting
NCT03720678 Phase I AB928 + Fluorouracil + Leucovorin + Oxaliplatin A Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Gastrointestinal (GI) Malignancies Recruiting
NCT03735628 Phase Ib/II Copanlisib + Nivolumab An Study to Evaluate the Safety and Efficacy of Copanlisib in Combination With Nivolumab in Patients With Advanced Solid Tumors Recruiting
NCT03775850 Phase Ib/II EDP1503 EDP1503 + Pembrolizumab A Study of EDP1503 in Patients With Colorectal Cancer, Breast Cancer, and Checkpoint Inhibitor Relapsed Tumors Recruiting
NCT03785210 Phase II Nivolumab + Tadalafil + Vancomycin Nivolumab (Anti-PD1), Tadalafil and Oral Vancomycin in People With Refractory Primary Hepatocellular Carcinoma or Liver Dominant Metastatic Cancer From Colorectal or Pancreatic Cancers Not yet recruiting
NCT03791398 Phase Ib/II Nivolumab + ONC201 BrUOG 379 Phase Ib/II Trial ONC201 + Nivolumab in MSS mCRC (379) Not yet recruiting
NCT03797326 Phase II Lenvatinib + Pembrolizumab Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) in Previously Treated Participants With Select Solid Tumors (MK-7902-005/E7080-G000-224/LEAP-005) Recruiting
NCT03802747 Phase I Durvalumab + Tremelimumab Durvalumab Immunotherapy Combined With Y-90 and SBRT for Colorectal Liver Metastases Not yet recruiting
NCT03844620 Phase II Regorafenib trifluridine/tipiracil hydrochloride Regorafenib + trifluridine/tipiracil hydrochloride Circulating Cell-Free Tumor DNA Testing in Guiding Treatment for Patients With Advanced or Metastatic Colorectal Cancer Recruiting
NCT03844750 Phase II Fluorouracil + Leucovorin + Oxaliplatin Pembrolizumab Pembrolizumab After Chemotherapy in Treating Patients With Colorectal Cancer That Has Spread to the Liver and Who Are Undergoing Liver Surgery Not yet recruiting
NCT03851614 Phase II Cediranib + Durvalumab Durvalumab + Olaparib Basket Combination Study of Inhibitors of DNA Damage Response, Angiogenesis and Programmed Death Ligand 1 in Patients With Advanced Solid Tumors (DAPPER) Recruiting
NCT03875313 Phase Ib/II CB-839 + Talazoparib Study of CB-839 (Telaglenastat) in Combination With Talazoparib in Patients With Solid Tumors Recruiting
NCT03879811 Phase II Nivolumab Temozolomide Determining the Effects of Temozolomide Followed by Nivolumab in Patients With Colorectal Cancer Recruiting